Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.00%
)
US TECH 100
24,150.07
(
0.07%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
103.02
(
2.35%
)
Bitcoin
72,377.57
(
-2.12%
)
News Focus
News Focus
Post# of 20689
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

y3maxx

Send PM Follow Ignore
Followers 3
Posts 1781
Boards Moderated 0
Alias Born 07/06/2004

y3maxx

Re: indigokid post# 8083

Wednesday, 01/04/2012 1:02:05 PM

Wednesday, January 04, 2012 1:02:05 PM

Post# of 20689
""despite the launch of Gilenya, an oral treatment made by Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ), in late 2010""

...Perhaps NVS cares very little of M copax success because of Gilenya?

...Who really knows just how supportive NVS is with M copax at the FDA?

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM

Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM

Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM

DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM

Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM

Start posting your company's news
Only $200 per official company press release!